• Facebook
  • X
  • Instagram
MYELOMA360
  • Home
  • MYBoard
  • MYInsights
  • Strategy & Consulting
  • Contact Us
Select Page

Triplet regimen extends OS in relapsed or refractory multiple myeloma

by | Nov 14, 2024 | Uncategorized

A triplet regimen extended OS compared with the current standard of care for patients with relapsed or refractory multiple myeloma, according to a topline data announcement.Patients with multiple myeloma often become refractory to first-line triplet or quadruplet...

QOL a Crucial Consideration During R/R Myeloma Treatment Decision-Making

by | Nov 12, 2024 | Uncategorized

Source: CureToday articles Patients with relapsed or refractory multiple myeloma should consider quality of life with survival when choosing the most suitable treatment option. Read More

FDA Receives Application Seeking Approval of Darzalex Faspro in Smoldering Myeloma

by | Nov 11, 2024 | Uncategorized

Source: CureToday articles If approved by the FDA, Darzalex Faspro may be the first treatment for smoldering multiple myeloma as compared to treating the disease once it progresses. Read More

KRd56 Versus KRd27 Shows Similar Effectiveness, Safety in R/R Multiple Myeloma

by | Nov 7, 2024 | Uncategorized

Source: CureToday articles In patients with relapsed or refractory multiple myeloma, KRd56 and KRd27 showed similar effectiveness and safety, but other treatment options may be better. Read More

Carvykti Effective for R/R Multiple Myeloma in Real-World Setting

by | Nov 5, 2024 | Uncategorized

Source: CureToday articles The CAR-T cell therapy Carvykti has been shown to be effective among patients outside the confines of a clinical trial. Read More

BRCA variants increase risk for multiple myeloma, particularly at younger age

by | Nov 4, 2024 | Uncategorized

Inherited variants in DNA repair genes such as BRCA1 and BRCA2 may increase risk for multiple myeloma, according to results of a retrospective study.Patients with pathogenic germline variants exhibited increased likelihood of having a family or personal history of...
« Older Entries
Next Entries »

Recent Content

  • Patient-reported outcome domains in multiple myeloma randomized controlled trials and association with survival outcomes
  • Peroxiredoxin 6 maintains mitochondrial homeostasis and promotes tumor progression through ROS/JNK/p38 MAPK signaling pathway in multiple myeloma
  • Deeper response predicts better outcomes in high-risk-smoldering-myeloma: results of the I-PRISM phase II clinical trial
  • Addition of Elotuzumab to Backbone Treatment Regimens for Multiple Myeloma: An Updated Meta-Analysis of Randomized Clinical Trials
  • Efficacy and safety of chimeric antigen receptor T cells targeting BCMA and GPRC5D in relapsed or refractory multiple myeloma
  • A Year of Resilience: Looking Back After a Myeloma Diagnosis
  • Real-World Outcomes Show Efficacy, Safety of Ciltacabtagene Autoleucel in Relapsed, Refractory Multiple Myeloma
  • Equecabtagene Autoleucel Shows Efficacy, Safety in Treatment of Patients With Heavily Pretreated Multiple Myeloma
  • Anitocabtagene autoleucel exhibits durable efficacy in high-risk advanced multiple myeloma
  • Integration of clinical outcomes and molecular features in extramedullary disease in multiple myeloma
  • Facebook
  • X
  • Instagram
©2016-2024 MYELOMA360
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking “Accept”, you consent to the use of ALL the cookies.
Do not sell my personal information.
SettingsAccept
Privacy & Cookies Policy

Privacy Overview

This website uses cookies to improve your experience while you navigate through the website. Out of these cookies, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies. But opting out of some of these cookies may have an effect on your browsing experience.
Necessary
Always Enabled
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
Non-necessary
Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.
SAVE & ACCEPT